The psoriatic arthritis market is projected to grow from $4.53bn in 2015 to approximately $12.6bn by 2025 in the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan, according to a report by GlobalData.

Titled 'PharmaPoint: Psoriatic Arthritis – Global Drug Forecast and Market Analysis to 2025', the report forecasts the psoriatic arthritis market to witness a compound annual growth rate of 10.74%.

An increased awareness of the disease and development of interleukin (IL)-17 inhibitors and are expected to be the major drivers of growth. Educational campaigns and an interdisciplinary approach to managing the condition have increased awareness of the disease.

As a result, the total number of treated cases in the 7MM is expected to increase from roughly 770,000 in 2015 to 1.2 million by 2025, according to GlobalData immunology analyst Alexandra Annis, MS.

"An increased awareness of the disease and development of interleukin (IL)-17 inhibitors and are expected to be the major drivers of growth."

Existing treatment options do not have long-term efficacy requiring patients to have a cycle through the drugs. New therapeutic options with strong clinical efficacy will provide patients and physicians with more choice.

The recent approval of Novartis’ IL-17 inhibitor Cosentyx has been welcomed by the psoriatic arthritis community. The drug shows the highest clinical efficacy of any biologic approved with X-ray assessment data demonstrating 84% of patients as showing no progression in structural joint damage over a period of two years of use.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The psoriatic arthritis market is expected to have a range of therapeutic options over the forecast period, including Eli Lilly’s Taltz (ixekizumab), AstraZeneca’s Lumicef (brodalumab) and Celgene’s oral therapy Otezla (apremilast).

Lumicef and Taltz are expected to emerge as the leading drugs in the market, with the latter expected to gross an estimated $1.42bn in total sales by 2025. New entrants, however, are expected to face difficulties in terms of increased choice and reduced drug costs.